TRACON Pharmaceutical (TCON) – Analyst EPS Change
-
Tracon Pharmaceuticals (TCON) PT Lowered to $8 at Needham & Company
-
Tracon Pharmaceuticals (TCON) PT Lowered to $6 at Stifel; 'Competitor Dalantercept Fails in RCC Adding Risk to the Anti-Angiogenesis Half of the Tracon Story'
Back to TCON Stock Lookup